Showing results (1431-1440 of 3,591) with videos related to
Sort By:
Pageof 360
Journal of Viral Hepatitis|July 2, 2013
Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis CZ M Younossi, M Stepanova, M Afendy, et al.Journal of Viral Hepatitis|July 2, 2013
Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis CK Yanagisawa, S Yue, H J van der Vliet, et al.Journal of Viral Hepatitis|June 9, 2012
Treating hepatitis C: current standard of care and emerging direct-acting antiviral agentsF Poordad, D DieterichJournal of Viral Hepatitis|June 9, 2012
Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximabG Geri, B Terrier, F Imbert-Bismut, et al.Journal of Viral Hepatitis|December 6, 2013
Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopeniaE Ogawa, N Furusyo, M Murata, et al.Journal of Viral Hepatitis|December 6, 2013
Maternal immunization promotes the immune response of neonates towards hepatitis B vaccineW Zhang, Z Guo, L Zhang, et al.Journal of Viral Hepatitis|December 6, 2013
A paucity of liver disease in Canadian Inuit with chronic hepatitis B virus, subgenotype B6 infectionG Y Minuk, S Macrury, J Uhanova, et al.Journal of Viral Hepatitis|October 31, 2013
The new paradigm of hepatitis C therapy: integration of oral therapies into best practicesN H Afdhal, S Zeuzem, R T Schooley, et al.Journal of Viral Hepatitis|October 31, 2013
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysisV Di Marco, L Covolo, V Calvaruso, et al.Journal of Viral Hepatitis|December 17, 2013
Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infectionU Mihm, M-W Welker, G Teuber, et al.Pageof 360